Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janice Pan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Advances in Therapy|April 7, 2019
Metastatic Renal Cell Cancer: An Analysis of Reimbursement DecisionsCarina Schey, Genevieve Meier, Janice Pan
IEEE Transactions on Image Processing : a Publication of the IEEE Signal Processing Society|February 13, 2018
Learning a Continuous-Time Streaming Video QoE ModelDeepti Ghadiyaram, Janice Pan, Alan C Bovik
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 25, 2017
The obesity paradox in ICU patientsJanice Pan, Robert Shaffer, Zeina Sinno, et al.
BMC Medical Research Methodology|January 30, 2025
Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinomaChristopher G Fawsitt, Janice Pan, Philip Orishaba, et al.
Journal of Medical Economics|January 28, 2026
Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling studyOliver Burn, Kate Molloy, Michio Kanekiyo, et al.
Value in Health Regional Issues|February 1, 2021
Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT TrialShunya Ikeda, Masatoshi Kudo, Namiki Izumi, et al.
Canadian Journal of Gastroenterology & Hepatology|March 8, 2021
The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian PerspectiveBrandon M Meyers, Arndt Vogel, Paul Marotta, et al.
Journal of Gastroenterology|February 22, 2019
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in JapanMasahiro Kobayashi, Masatoshi Kudo, Namiki Izumi, et al.
Plos One|August 17, 2013
Loss of ACE2 exacerbates murine renal ischemia-reperfusion injuryFei Fang, George Chu Liu, Xiaohua Zhou, et al.
The Oncologist|July 26, 2022
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell CarcinomaCristiane Bergerot, Sun Young Rha, Sumanta Pal, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Advances in Therapy|April 7, 2019
Metastatic Renal Cell Cancer: An Analysis of Reimbursement DecisionsCarina Schey, Genevieve Meier, Janice Pan
IEEE Transactions on Image Processing : a Publication of the IEEE Signal Processing Society|February 13, 2018
Learning a Continuous-Time Streaming Video QoE ModelDeepti Ghadiyaram, Janice Pan, Alan C Bovik
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 25, 2017
The obesity paradox in ICU patientsJanice Pan, Robert Shaffer, Zeina Sinno, et al.
BMC Medical Research Methodology|January 30, 2025
Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinomaChristopher G Fawsitt, Janice Pan, Philip Orishaba, et al.
Journal of Medical Economics|January 28, 2026
Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling studyOliver Burn, Kate Molloy, Michio Kanekiyo, et al.
Value in Health Regional Issues|February 1, 2021
Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT TrialShunya Ikeda, Masatoshi Kudo, Namiki Izumi, et al.
Canadian Journal of Gastroenterology & Hepatology|March 8, 2021
The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian PerspectiveBrandon M Meyers, Arndt Vogel, Paul Marotta, et al.
Journal of Gastroenterology|February 22, 2019
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in JapanMasahiro Kobayashi, Masatoshi Kudo, Namiki Izumi, et al.
Plos One|August 17, 2013
Loss of ACE2 exacerbates murine renal ischemia-reperfusion injuryFei Fang, George Chu Liu, Xiaohua Zhou, et al.
The Oncologist|July 26, 2022
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell CarcinomaCristiane Bergerot, Sun Young Rha, Sumanta Pal, et al.
Pageof 2